4Back SA, Riddle A, Dean J, et al. The instrumented fetal sheep as a model of cerebral white matter injury in the prema- ture infant [J] .Neurotherapeatics, 2012, 9 (2): 359- 370.
5Kapitanoviff Vidak H, Catela Ivkoviff T, Jokic M, et al. Theassociation between proinflammatory cytokine polymorphisms and cerebral palsy in very preterm infants [ J ] . Cytokine, 2012, 58 (1): 57-64.
6Kwon DR, Park GY. Differences in lateral ankie ligaments be- tween affected and unaffected legs in children with spastic hemiplegic cerebral palsy [J] . J Ultrasound Med, 2013, 32 (2) : 313 -317.
7Slaboda JC, Lauer RT, Keshner EA. Postural responses of a-dults with cerebral palsy to combined base of support and visual field rotation [J]. IEEE Trans Neural Syst Rehabil Eng, 2013, ,21 (2) : 218 -224.
8Chrysagis N; Skordilis EK, Stavrou N, et al. The effect: of treadmill training on gross motor function and walking speed in ambulatory adoleseents with cerebral palsy: a randomized controlled trial [J] . Am J Phys Med Rehabil, 2012, 91 (9) : 747 - 760.
9Gupta S, Raja K. Responsiveness of Edinburgh Visual Gait Score to orthopedic surgical intervention of the lower limbs in children with cerebral palsy [J]. Am J Phys Med Rehabil, 2012, 91 (9): 761-767.
5WHO expert consultation on rabies: first report. Geneva: WHO, 2004.
6Discussion on WHO requirements for rabies vaccine for human use potency assay. 20 May 2003. Geneva: WHO. 2003.
7Nagarajan T, Reddy GS, Mohana Subramanian B, et al A simple immuno-capture ELISA to estimate rabies viral glycoprotein antigen in vaccine manufacture. Biologicals, 2006, 34(1): 21-27.
8WorldHealth Organization. WHO expert consultation on rabies[M]. 1st ed. Geneva: World Health Organization, 2004 : 42-47.
9World Health Organization. Discussion on WHO requirementsfor rabies vaccine for human use potency assay [M]. Geneva :World Health Organization, 2003 : 4-5.
10KobayashiM, Kimura H,Liao J, et al. Measurement of mousetime-resolved fluoroimmunoassay[J]. Anal Sci, 2003,19(2): 205-210.
